Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
It is the target for several FDA-approved antidiabetic medications called incretin mimetics: These incretin mimetics are glucagon-like peptide 1 (GLP-1) analogs that mimic the physiological action of GLP-1 and thereby potentiates the incretin effect in type 2 diabetic patients
2014;106(1):e36
These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist
Clinical Recommendations If you have diabetes and are considering berberine: Never start berberine without discussing it with your GP or diabetes specialist nurse Increase blood glucose monitoring frequency if berberine is commenced Be vigilant for hypoglycaemia symptoms: sweating, tremor, hunger, confusion, or palpitations Your diabetes medication doses may require adjustment under clinical supervision Keep fast-acting glucose (e.g., glucose tablets, sugary drink) readily available and follow your local hypoglycaemia management plan NICE guidelines (NG28) for type 2 diabetes management do not include berberine as a recommended treatment option
